|
|
| (14 intermediate revisions by 2 users not shown) |
| Line 2: |
Line 2: |
| [[Image:Parainfluenza virus TEM PHIL 271 lores.jpg|right|thumb|200px|right|Transmission electron micrograph of parainfluenza virus. Two intact particles and free filamentous nucleocapsid]] | | [[Image:Parainfluenza virus TEM PHIL 271 lores.jpg|right|thumb|200px|right|Transmission electron micrograph of parainfluenza virus. Two intact particles and free filamentous nucleocapsid]] |
| {{Human parainfluenza virus}} | | {{Human parainfluenza virus}} |
| | '''For patient information click [[Human parainfluenza viruses (patient information)|here]].''' |
| | |
| {{CMG}} | | {{CMG}} |
|
| |
|
| ==Clinical features== | | ==[[Human parainfluenza viruses overview|Overview]]== |
| | |
| Human parainfluenza viruses (HPIVs) are second to respiratory syncytial virus (RSV) as a common cause of lower respiratory tract disease in young children. Similar to RSV, HPIVs can cause repeated infections throughout life, usually manifested by an upper respiratory tract illness (e.g., a cold and/or sore throat). HPIVs can also cause serious lower respiratory tract disease with repeat infection (e.g., pneumonia, bronchitis, and bronchiolitis), especially among the elderly, and among patients with compromised immune systems. Each of the four HPIVs has different clinical and epidemiologic features. The most distinctive clinical feature of HPIV-1 and HPIV-2 is croup (i.e., laryngotracheobronchitis); HPIV-1 is the leading cause of croup in children, whereas HPIV-2 is less frequently detected. Both HPIV-1 and -2 can cause other upper and lower respiratory tract illnesses. HPIV-3 is more often associated with bronchiolitis and pneumonia. HPIV-4 is infrequently detected, possibly because it is less likely to cause severe disease. The incubation period for HPIVs is generally from 1 to 7 days.
| |
| | |
| ==The viruses==
| |
| | |
| HPIVs are negative-sense, single-stranded RNA viruses that possess fusion and hemagglutinin-neuraminidase glycoprotein "spikes" on their surface. There are four serotypes types of HPIV (1 through 4) and two subtypes (4a and 4b). The virion varies in size (average diameter between 150 and 300 nm) and shape, is unstable in the environment (surviving a few hours on environmental surfaces), and is readily inactivated with soap and water.
| |
| | |
| ===Types===
| |
| | |
| The four serotypes include:
| |
| | |
| * Human parainfluenza virus type 1: HPIV-1 (most common cause of [[croup]]; also other upper and lower respiratory tract illnesses typical)
| |
| * Human parainfluenza virus type 2: HPIV-2 (causes croup and other upper and lower respiratory tract illnesses)
| |
| * Human parainfluenza virus type 3: HPIV-3 (associated with [[bronchiolitis]] and [[pneumonia]])
| |
| * Human parainfluenza virus type 4: HPIV-4 (includes subtypes 4a and 4b)
| |
| | |
| ==Epidemiologic features==
| |
| | |
| HPIVs are spread from respiratory secretions through close contact with infected persons or contact with contaminated surfaces or objects. Infection can occur when infectious material contacts mucous membranes of the eyes, mouth, or nose, and possibly through the inhalation of droplets generated by a sneeze or cough. HPIVs can remain infectious in aerosols for over an hour. HPIVs are ubiquitous and infect most people during childhood. The highest rates of serious HPIV illnesses occur among young children. Serologic surveys have shown that 90% to 100% of children aged 5 years and older have antibodies to HPIV- 3, and about 75% have antibodies to HPIV-1 and -2. The different HPIV serotypes differ in their clinical features and seasonality. HPIV-1 causes biennial outbreaks of croup in the fall (presently in the United States during odd numbered years). HPIV-2 causes annual or biennial fall outbreaks. HPIV-3 peak activity occurs during the spring and early summer months each year, but the virus can be isolated throughout the year.
| |
| | |
| ==Diagnosis==
| |
|
| |
|
| Infection with HPIVs can be confirmed in two ways: 1) by isolation and identification of the virus in cell culture or by direct detection of the virus in respiratory secretions (usually, collected within one week of onset of symptoms) using immunofluorescence, enzyme immunoassay, or polymerase chin reaction assay, and 2) by demonstration of a significant rise in specific IgG antibodies between appropriately collected paired serum specimens or specific IgM antibodies in a single serum specimen.
| | ==[[Human parainfluenza viruses historical perspective|Historical Perspective]]== |
| | ==[[Human parainfluenza viruses classification|Classification]]== |
| | ==[[Human parainfluenza viruses pathophysiology|Pathophysiology]]== |
| | ==[[Human parainfluenza viruses causes|Causes]]== |
|
| |
|
| ==Prevention== | | ==[[Human parainfluenza viruses differential diagnosis|Differentiating Human parainfluenza viruses from other Disorders]]== |
|
| |
|
| No vaccine is currently available to protect against infection caused by any of the HPIVs; however, researchers are developing vaccines against HPIV-1 and -3 infections. Passively acquired maternal antibodies may play a role in protection from HPIV types 1 and 2 in the first few months of life, highlighting the importance of breast-feeding. Strict attention to infection-control practices should decrease or prevent spread of infection. Frequent handwashing and not sharing items such as cups, glasses, and utensils with an infected person should decrease the spread of virus to others. Excluding children with colds or other respiratory illnesses (without fever) who are well enough to attend child care or school settings will probably not decrease the spread of HPIVs, because the viruses are often spread in the early stages of illness. In a hospital setting, spread of HPIVs can and should be prevented by strict attention to contact precautions, such as handwashing and wearing of protective gowns and gloves.
| | ==[[Human parainfluenza viruses epidemiology and demographics|Epidemiology and Demographics]]== |
| | ==[[Human parainfluenza viruses risk factors|Risk Factors]]== |
| | ==[[Human parainfluenza viruses natural history, complications and prognosis|Natural History, Complications and Prognosis]]== |
|
| |
|
| ==References== | | ==Diagnosis== |
| | | [[Human parainfluenza viruses history and symptoms|History and Symptoms]] | [[Human parainfluenza viruses physical examination|Physical Examination]] | [[Human parainfluenza viruses laboratory findings|Laboratory Findings]] | [[Human parainfluenza viruses chest x ray|Chest X Ray]] | [[Human parainfluenza viruses other imaging findings|Other Imaging Findings]] | [[Human parainfluenza viruses other diagnostic studies|Other Diagnostic Studies]] |
| * American Academy of Pediatrics. Parainfluenza Viral Infections. In: Peter G, ed. 1997 Red Book: Report of the Committee on Infectious Diseases. 24th ed. Elk Grove Village, IL: American Academy of Pediatrics; 1997: 379.
| |
| * Collins PL, Chanock RM, McIntosh K. Parainfluenza viruses. In: Fields BN, Knipe DM, Howley PM, eds. Fields Virology. 3rd ed. Philadelphia: Lippincott-Raven; 1995: 1205-41.
| |
| * Glezen WP, Denny FW. Parainfluenza Viruses In: Evans A, Kaslow R, eds. Viral Infections in Humans: epidemiology and control. 4th ed. New York: Plenum; 1997:551-67.
| |
|
| |
|
| | ==Treatment== |
| | [[Human parainfluenza viruses medical therapy|Medical Therapy]] | [[Human parainfluenza viruses prevention|Prevention]] | [[Human parainfluenza viruses cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Human parainfluenza viruses future or investigational therapies|Future or Investigational Therapies]] |
|
| |
|
| | ==Case Studies== |
| | [[Human parainfluenza viruses case study one|Case #1]] |
|
| |
|
| [[Category:Pulmonology]] | | [[Category:Pulmonology]] |
| [[Category:Viruses]] | | [[Category:Viruses]] |
|
| |
|
| [[de:Parainfluenza]]
| | |
| [[fr:Parainfluenza]]
| |
| [[pl:Wirus paragrypy]]
| |
|
| |
|
| {{jb1}} | | {{jb1}} |
| {{WH}} | | {{WH}} |
| {{WS}} | | {{WS}} |
